贝伐珠单抗治疗放射性脑坏死研究进展  

Research progress on bevacizumab in the treatment of radiation-induced brain necrosis

作　　者：韩帅[1] 王文岩[1] 周欢娣 薛晓英[1] Shuai Han;Wenyan Wang;Huandi Zhou;Xiaoying Xue(Department of Radiotherapy,the Second Hospital of Hebei Medical University,Shijiazhuang 050000,China)

机构地区：[1]河北医科大学第二附属医院放疗科,石家庄050000

出　　处：《中华放射肿瘤学杂志》2022年第8期737-740,共4页Chinese Journal of Radiation Oncology

摘　　要：放射性脑坏死是原发性或继发性脑肿瘤以及头颈部肿瘤放疗后的严重晚期、不可逆的并发症,尚无有效的治疗方法。近几年来,贝伐珠单抗越来越多地被用于放射性脑坏死的治疗,并确定有一定疗效,可以改善患者生存,但关于最佳治疗时机、方案等一直存在争议,缺乏基本共识,本文就这方面研究进展进行简要回顾。Radiation-induced brain necrosis(RIBN)is a serious late and irreversible complication after radiation therapy for primary or secondary brain tumors as well as head and neck tumors,and there is no effective treatment.In recent years,bevacizumab has been increasingly applied in the treatment of RIBN,which has been proven to yield certain efficacy and improve patient survival.However,the optimal treatment timing and regimen have been controversial and lack of basic consensus.In this article,research progress on these issues was briefly reviewed.

关 键 词：放射性脑坏死 贝伐珠单抗 放射疗法 脑肿瘤 

分 类 号：R730.55[医药卫生—肿瘤]